BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 16686530)

  • 1. Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
    Agnes RS; Lee YS; Davis P; Ma SW; Badghisi H; Porreca F; Lai J; Hruby VJ
    J Med Chem; 2006 May; 49(10):2868-75. PubMed ID: 16686530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
    Yamamoto T; Nair P; Vagner J; Largent-Milnes T; Davis P; Ma SW; Navratilova E; Moye S; Tumati S; Lai J; Yamamura HI; Vanderah TW; Porreca F; Hruby VJ
    J Med Chem; 2008 Mar; 51(5):1369-76. PubMed ID: 18266313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists.
    Yamamoto T; Nair P; Davis P; Ma SW; Navratilova E; Moye S; Tumati S; Lai J; Vanderah TW; Yamamura HI; Porreca F; Hruby VJ
    J Med Chem; 2007 Jun; 50(12):2779-86. PubMed ID: 17516639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
    Lee YS; Agnes RS; Badghisi H; Davis P; Ma SW; Lai J; Porreca F; Hruby VJ
    J Med Chem; 2006 Mar; 49(5):1773-80. PubMed ID: 16509592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain.
    Hruby VJ; Agnes RS; Davis P; Ma SW; Lee YS; Vanderah TW; Lai J; Porreca F
    Life Sci; 2003 Jun; 73(6):699-704. PubMed ID: 12801591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties.
    Fujita Y; Tsuda Y; Li T; Motoyama T; Takahashi M; Shimizu Y; Yokoi T; Sasaki Y; Ambo A; Kita A; Jinsmaa Y; Bryant SD; Lazarus LH; Okada Y
    J Med Chem; 2004 Jul; 47(14):3591-9. PubMed ID: 15214786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonists.
    Yamamoto T; Nair P; Jacobsen NE; Vagner J; Kulkarni V; Davis P; Ma SW; Navratilova E; Yamamura HI; Vanderah TW; Porreca F; Lai J; Hruby VJ
    J Med Chem; 2009 Aug; 52(16):5164-75. PubMed ID: 20560643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel ligands lacking a positive charge for the delta- and mu-opioid receptors.
    Schiller PW; Berezowska I; Nguyen TM; Schmidt R; Lemieux C; Chung NN; Falcone-Hindley ML; Yao W; Liu J; Iwama S; Smith AB; Hirschmann R
    J Med Chem; 2000 Feb; 43(4):551-9. PubMed ID: 10691681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors.
    Lee YS; Agnes RS; Davis P; Ma SW; Badghisi H; Lai J; Porreca F; Hruby VJ
    J Med Chem; 2007 Jan; 50(1):165-8. PubMed ID: 17201419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cis-4-amino-L-proline residue as a scaffold for the synthesis of cyclic and linear endomorphin-2 analogues.
    Mollica A; Pinnen F; Stefanucci A; Feliciani F; Campestre C; Mannina L; Sobolev AP; Lucente G; Davis P; Lai J; Ma SW; Porreca F; Hruby VJ
    J Med Chem; 2012 Apr; 55(7):3027-35. PubMed ID: 22394120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
    Tóth G; Ioja E; Tömböly C; Ballet S; Tourwé D; Péter A; Martinek T; Chung NN; Schiller PW; Benyhe S; Borsodi A
    J Med Chem; 2007 Jan; 50(2):328-33. PubMed ID: 17228874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors.
    Lee YS; Petrov R; Park CK; Ma SW; Davis P; Lai J; Porreca F; Vardanyan R; Hruby VJ
    J Med Chem; 2007 Nov; 50(22):5528-32. PubMed ID: 17927164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological activities of cyclic lanthionine enkephalin analogues: delta-opioid receptor selective ligands.
    Rew Y; Malkmus S; Svensson C; Yaksh TL; Chung NN; Schiller PW; Cassel JA; DeHaven RN; Taulane JP; Goodman M
    J Med Chem; 2002 Aug; 45(17):3746-54. PubMed ID: 12166947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
    Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
    J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
    Li T; Shiotani K; Miyazaki A; Tsuda Y; Ambo A; Sasaki Y; Jinsmaa Y; Marczak E; Bryant SD; Lazarus LH; Okada Y
    J Med Chem; 2007 Jun; 50(12):2753-66. PubMed ID: 17497839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the delta-opioid receptor.
    Liao S; Alfaro-Lopez J; Shenderovich MD; Hosohata K; Lin J; Li X; Stropova D; Davis P; Jernigan KA; Porreca F; Yamamura HI; Hruby VJ
    J Med Chem; 1998 Nov; 41(24):4767-76. PubMed ID: 9822547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2.
    Li T; Fujita Y; Tsuda Y; Miyazaki A; Ambo A; Sasaki Y; Jinsmaa Y; Bryant SD; Lazarus LH; Okada Y
    J Med Chem; 2005 Jan; 48(2):586-92. PubMed ID: 15658871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
    Li T; Fujita Y; Shiotani K; Miyazaki A; Tsuda Y; Ambo A; Sasaki Y; Jinsmaa Y; Marczak E; Bryant SD; Salvadori S; Lazarus LH; Okada Y
    J Med Chem; 2005 Dec; 48(25):8035-44. PubMed ID: 16335927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.